2025 Environmental, Social and Governance (ESG) Report Summary
Summary of the 2025 Environmental, Social and Corporate Governance (ESG) Report of North China Pharmaceutical Co., Ltd.
Securities code: 600812 Securities abbreviation: North China Pharmaceutical North China Pharmaceutical Co., Ltd.
1/6
Summary of the 2025 Environmental, Social and Corporate Governance (ESG) Report of North China Pharmaceutical Co., Ltd.
Section 1 Important Tips
This summary comes from the full text of the 2025 Environmental, Social and Corporate Governance (ESG) Report. In order to fully understand the relevant impacts, risks and opportunities of the company's environmental, social and corporate governance issues, as well as the company's sustainable development strategy and other related matters, investors should go to the www.sse.com.cn website to carefully read the full text of the 2025 Environmental, Social and Corporate Governance (ESG) Report.
The 2025 environmental, social and corporate governance (ESG) report was reviewed and approved by the company’s board of directors.
2/6
Summary of the 2025 Environmental, Social and Corporate Governance (ESG) Report of North China Pharmaceutical Co., Ltd.
Section 2 Reporting Basic Situation
- Basic information
Stock code 600812
Company abbreviation North China Pharmaceutical
Company Name North China Pharmaceutical Co., Ltd.
Reporting Scope North China Pharmaceutical Co., Ltd. and its subsidiaries (branches)
From January 1, 2025 to December 31, 2025, some contents are based on the disclosed time range.
Exposure needs to be appropriately extended in time frame
The State-owned Assets Supervision and Administration Commission of the State Council "Guiding Opinions on the High-Standard Fulfillment of Social Responsibility by Central Enterprises in the New Era"
State-owned Assets Supervision and Administration Commission of the State Council "Guiding Opinions on Better Fulfilling Social Responsibility of State-owned Enterprises"
Shanghai Stock Exchange "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 14 - Sustainability Reporting (Trial)"
China Enterprise Reform and Development Research Association and Responsibility Cloud Research Institute's "Guidelines for Sustainable Development Reports that Chinese Enterprises Can Prepare (CASS-ESG 6.0)"
ESG Branch of China Pharmaceutical Business Association and Responsible Cloud Research Institute "ESG Information Disclosure Guide for the Pharmaceutical Industry"
United Nations Sustainable Development Goals (SDGs)
Global Reporting Initiative Sustainability Reporting Standards (GRI Standards)
International Organization for Standardization (ISO) "Implementing Environmental, Social and Governance (ESG)"
Principles Framework
- Sustainable development governance system
(1) Whether there is a governance body responsible for managing and supervising the impacts, risks and opportunities related to sustainable development: √Yes, the name of the governance body is the decision-making level - Board of Directors, Strategy (Investment Decision-making) and Sustainable Development Committee; Management - Corporate Management Department; Execution level - ESG Implementation Working Group. [Tip: Please fully list the constituent organizations of the governance system] □No
(2) Whether an internal reporting mechanism for sustainable development information has been established: √Yes, the reporting method and frequency is annual □
No
(3) Whether a sustainable development supervision mechanism has been established, such as internal control system, supervision procedures, supervision measures and assessment status, etc.: √ Yes, the relevant systems or measures have established a three-level ESG management structure for the company with clear rights and responsibilities: “decision-making layer, management layer and execution layer” □ No
- Communication with stakeholders
Whether the company carries out stakeholder communication and disclosure through interviews, seminars, questionnaires, etc.: √Yes ☐No
Stakeholders Content of concern Communication method Government and regulatory agencies Safety and compliance with the law, compliance with the law Policy instructions, work reports, information tax, promotion of local economic development, letter submission, on-site inspection
3/6
Summary of the 2025 Environmental, Social and Corporate Governance (ESG) Report of North China Pharmaceutical Co., Ltd.
Timely and standardized information disclosure
Shareholders and investors Corporate governance, risk control, information Shareholders’ meetings, announcements and notices, finance
Disclosure, Returns and Growth Reporting
Customers Integrity in contract performance, products and services, guarantees Business visits, customer discussions, customer protection of customer rights, improvement of customer satisfaction Satisfaction survey
degree
Employees Protect employee rights and interests, assist employees in forming trade unions and employee representative conferences, employee leaders, establish trade union systems, improve welfare and care activities, and professional ability training
benefit system
Partners drive industry development, partners work together through open bidding, industry forums, win-win exchanges, implement responsible procurement, and achieve public cooperation
flat operation
Community and the public Community welfare, energy conservation and emission reduction, protection of public welfare projects, implementation of environmental policies, ecological environment, rational use of resources, environmental information disclosure
Tackling climate change
- Dual importance assessment results
Serial number Company ESG reporting agenda Importance analysis Corresponding to the name of the sustainability report topic of the Shanghai Stock Exchange Name of the guideline topic
□Financial importance
Energy consumption and resource management
1 □Impact Importance Energy Utilization
reason
√Double importance
□Financial importance
2 Coping with climate change √ Importance of impact Coping with climate change □ Dual importance
□Financial importance
3 Waste management √ Importance of impact Waste treatment □ Dual importance
□Financial importance
4 Pollutant emissions □ Impact importance Pollutant emissions √ Dual importance
□Financial importance
ecosystem and life
5 √Importance of impact Ecosystem and biodiversity conservationBiodiversity conservation
□Double importance
□Financial importance
6 Environmental Compliance Management √ Importance of Impact Environmental Compliance Management □ Dual Importance
□Financial importance
7 Water Utilization √ Importance of Impact Water Utilization □ Dual Importance
4/6
Summary of the 2025 Environmental, Social and Corporate Governance (ESG) Report of North China Pharmaceutical Co., Ltd.
Serial number Company ESG reporting agenda Importance analysis Corresponding to the name of the sustainability report topic of the Shanghai Stock Exchange Name of the guideline topic
□Financial importance
8 Circular Economy √ Importance of Impact Circular Economy □ Dual Importance
□Financial importance
9 Supply Chain Management □ Impact Importance Supply Chain Security √ Dual Importance
□Financial importance
Product quality and safety
10 □Importance of impact Product and service safety and quality
√Double importance
□Financial importance
11 Employee Growth □ Impact Importance Employees
√Double importance
□Financial importance
12 R&D Innovation □ Impact Importance Innovation Driven √ Dual Importance
□Financial importance
information security and privacy
13 √ Importance of impact Data security and customer privacy protection
□Double importance
□Financial importance
Treat small and medium-sized enterprises equally
14 √ Importance of impact Treat small and medium-sized enterprises equally
□Double importance
□Financial importance
15 Drug accessibility √ Importance of impact Product and service safety and quality □ Dual importance
√Financial importance
16 Drug recall/recovery □ Impact importance Product and service safety and quality □ Dual importance
□Financial importance
17 Science and Technology Ethics √Importance of Impact Science and Technology Ethics □Double Importance
□Financial importance
18 Rural Revitalization √ Importance of Impact Rural Revitalization □ Dual Importance
□Financial importance
19 Social Contribution √ Importance of Impact Social Contribution □ Dual Importance
5/6
Summary of the 2025 Environmental, Social and Corporate Governance (ESG) Report of North China Pharmaceutical Co., Ltd.
Serial number Company ESG reporting agenda Importance analysis Corresponding to the name of the sustainability report topic of the Shanghai Stock Exchange Name of the guideline topic
√Financial importance
20 Business ethics □ Impact importance Anti-commercial bribery and anti-corruption □ Dual importance
□Financial importance
stakeholder gap
21 √Impact importance Communicate with stakeholders
□Double importance
√Financial importance
Anti-commercial bribery and
22 □ Impact importance Anti-commercial bribery and anti-corruption Anti-corruption
□Double importance
□Financial importance
23 Anti-unfair competition √ Importance of impact Anti-unfair competition □ Dual importance
□Financial importance
24 Due Diligence √Significance of Impact Due Diligence
□Double importance
Issues that are not important to the company include: green operations, hazardous chemicals management, and ESG governance issues. Although the issues are not important, the results of the issue identification have been reflected in this year’s Environmental, Social and Corporate Governance (ESG) report. At the same time, in the relevant chapters, the progress of the work related to the above issues in this year is introduced.
6/6